If patients do not have a sequence variant in the KRAS gene, the National Comprehensive Cancer Network (NCCN) guidelines for patients undergoing treatment for CRC state that testing for BRAF p.Val600Glu should be considered prior to the use of anti-EGFR antibodies (cetuximab and panitumumab). This evidence concerns the gene KRAS and colorectal carcinoma.